Respiratory Syncytial Virus (RSV)

Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use

Summary of Kuwait’s updated RSV prevention policy

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across  two consecutive RSV seasons

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

An easy guide to use Nirsevimab